secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dare Bioscience, Inc. (DARE)
CIK:        0001401914
Form:       8-K
Filed at:   2026-03-26T23:59:59+00:00
Accession:  0001493152-26-012902
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Daré Bioscience FY2025: $24.7M cash, $20.8M equity proceeds; DARE to PLAY revenue expected Q2 2026
--------------------------------------------------------------------------------

- Cash and cash equivalents $24.7M at Dec 31, 2025; working capital $3.4M.
- Received $20.8M net from at-the-market equity program and equity line in 2025.
- Non-dilutive funding: $13.6M Gates Foundation, $4.5M ARPA-H, $1.3M NIH in 2025.
- SG&A $8.8M (down from $9.2M in 2024); R&D $5.5M (down from $14.3M); contra-R&D $16.4M from grants.
- Expects DARE to PLAY product revenue and Flora Sync LF5 consumer revenue to begin Q2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401914/000149315226012902/0001493152-26-012902-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401914/000149315226012902/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-012902

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer